Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04286399 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Asian Diabetes Outcomes Prevention Trial

Study acronym: ADOPT
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 30, 2021 (before its estimated June 30, 2022 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Jun 30, 2021 to Jun 30, 2022
    • Start date changed from estimate of Mar 1, 2020 to Jul 1, 2019
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this study is to identify patients with DM at high risk of CVD using elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels (\>125pg/mL), and (2) intensify therapy using renin-angiotensin system (RAS) antagonists, beta-blockers and sodium glucose co-transporter-2 inhibitors (SGLT2i) for primary prevention of cardiovascular events in this high-risk DM population.
Trial Details
NCT Number NCT04286399
Lead Sponsor National Heart Centre Singapore
Collaborators: Singapore General Hospital, Mackay Memorial Hospital, National Taiwan University Hospital, Peking University People's Hospital, Medanta, The Medicity, India, Public Health Foundation of India, Putrajaya Hospital, Malaysia, Universiti Teknologi Mara
Conditions
(from sponsor)		 Diabetes Mellitus, Cardiovascular Diseases
Related terms Cardiovascular Diseases, Diabetes Mellitus
Enrollment 2,400 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov